Who are we?


Signup for

Online registration

Log in to register
your trial

Search a trial




van CCT (UK)

van CCT (UK)

Vasodilators in cold type Complex Regional Pain Syndrome.

- candidate number1939
- NTR NumberNTR571
- Date ISRCTN created14-feb-2006
- date ISRCTN requested3-feb-2006
- Date Registered NTR20-jan-2006
- Secondary IDsN/A 
- Public TitleVasodilators in cold type Complex Regional Pain Syndrome.
- Scientific TitleA double blind, randomized, placebo controlled trial of isosorbide dinitrate and tadalafil in cold type complex regional pain syndrome.
- ACRONYMVasCoTyC study
- hypothesisNitric oxide depending and independing vasodilation in patients with disused, cold type CRPS, will regenerate blood tissue distribution and consequently improve mobility and quality of life factors.
- Healt Condition(s) or Problem(s) studiedCold type complex regional pain syndrome
- Inclusion criteria1. Men and women between 18 and 65 years;
2. Established diagnosis of CRPS-1 according to the Bruehl / Budapest criteria.
- Exclusion criteria1. Coronary atherosclerosis or cerebral sclerosis;
2. Recent heart infarction;
3. Increased intracranial pressure;
4. Severe hypotension;
5. Myocardium insufficiency;
6. Damage of the central nervous system;
7. Contraindication of nitrates;
8. Inflammation of joints;
9. Use of corticosteroids or immunosuppressives;
10. Unable to fill in questionnaires.
- mec approval receivedyes
- multicenter trialno
- randomisedyes
- masking/blindingDouble
- controlPlacebo
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 1-feb-2006
- planned closingdate31-dec-2007
- Target number of participants76
- InterventionsSubjects are assigned to receive either 1 gram ISDN ointment 1% or placebo 4 times daily (groups 1 and 2) or 1 tablet of 10 mg tadalafil or palcebo daily (groups 3 and 4). The treatment period will be 10 weeks.
- Primary outcomeTissue blood distribution (thermography and Doppler flow).
- Secondary outcomePain, mobility and quality of life.
- TimepointsN/A
- Trial web siteN/A
- statusinclusion stopped: follow-up
- Sponsor/Initiator Erasmus Medical Center, Rotterdam
- Funding
(Source(s) of Monetary or Material Support)
Ministry of Economic Affairs, Eli Lilly Nederland B.V., The Reflex Sympathetic Dystrophy Syndrome Association (RSDSA, USA)
- PublicationsN/A
- Brief summaryIn most cases, adequate pharmacotherapeutic treatment of patients with complex regional pain syndrome type 1 (CRPS1, formerly indicated as post-traumatic dystrophy) in an extremity, who left the acute phase of the disease, is not available. Some pain relief could be obtained, but recovery of the neuro-inflammatory signs of the disease is barely achieved. Chronic CRPS1 could even lead to amputation of the dystrophic hand. Usually this is a direct effect of unbearable continuous pain and disuse of the extremity. Evidence has been found that both disuse and damages of nerve endings could lead to obstructions in the blood distribution of the involved extremity. Improvement of the blood distribution through nitric oxide - cyclic guanosine monophosphate (NO-cGMP) induced vasodilation could attribute to the recovery of this invalidating disease. Therefore, patients will be treated either with isosorbide dinitrate (ISDN), Tadalafil or placebo. In combination with an intensive physiotherapeutic program, this approach could diminish the progression of the disease, stabilize or even cause complete recovery in the patient. In this project, monitoring the patient during the treatment will be achieved by means of objective parameters such as Doppler flow and computer assisted videothermography, whereas clinically important parameters such as pain intensity, mobility and quality of life are registered. Furthermore, blood samples and blister fluid from both the involved and uninvolved extremity will be subjected to measurements of biochemical mediators. These data will provide detailed information of vascular changes in relation to the experience of pain and immobility. Treatment by ISDN or Tadalafil could improve chronic phase CRPS1 and furthermore provide more insight in mechanisms underlying this disabling disease.
- Main changes (audit trail)
- RECORD20-jan-2006 - 1-feb-2010

  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar